IL189945A0 - Novel 2-phenyl-imidazo[4,5-b]pyridine derivatives as inhibitors of glycogen synthase kinase for the treatment of dementia and neurodegenerative disorders - Google Patents

Novel 2-phenyl-imidazo[4,5-b]pyridine derivatives as inhibitors of glycogen synthase kinase for the treatment of dementia and neurodegenerative disorders

Info

Publication number
IL189945A0
IL189945A0 IL189945A IL18994508A IL189945A0 IL 189945 A0 IL189945 A0 IL 189945A0 IL 189945 A IL189945 A IL 189945A IL 18994508 A IL18994508 A IL 18994508A IL 189945 A0 IL189945 A0 IL 189945A0
Authority
IL
Israel
Prior art keywords
imidazo
dementia
inhibitors
phenyl
novel
Prior art date
Application number
IL189945A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Soderman Peter
Rotticci Didier
Rein Tobias
Gyback Helena
Arvidsson Per I
Arzel Erwan
Burrows Jeremy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Soderman Peter, Rotticci Didier, Rein Tobias, Gyback Helena, Arvidsson Per I, Arzel Erwan, Burrows Jeremy filed Critical Astrazeneca Ab
Publication of IL189945A0 publication Critical patent/IL189945A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL189945A 2005-10-03 2008-03-04 Novel 2-phenyl-imidazo[4,5-b]pyridine derivatives as inhibitors of glycogen synthase kinase for the treatment of dementia and neurodegenerative disorders IL189945A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502173 2005-10-03
PCT/SE2006/001115 WO2007040439A1 (en) 2005-10-03 2006-10-02 New compounds ii

Publications (1)

Publication Number Publication Date
IL189945A0 true IL189945A0 (en) 2008-08-07

Family

ID=37906402

Family Applications (1)

Application Number Title Priority Date Filing Date
IL189945A IL189945A0 (en) 2005-10-03 2008-03-04 Novel 2-phenyl-imidazo[4,5-b]pyridine derivatives as inhibitors of glycogen synthase kinase for the treatment of dementia and neurodegenerative disorders

Country Status (16)

Country Link
US (1) US20080255106A1 (enExample)
EP (1) EP1934217A4 (enExample)
JP (1) JP2009510162A (enExample)
KR (1) KR20080057334A (enExample)
CN (1) CN101321754A (enExample)
AR (1) AR057525A1 (enExample)
AU (1) AU2006297889A1 (enExample)
BR (1) BRPI0616663A2 (enExample)
CA (1) CA2624869A1 (enExample)
IL (1) IL189945A0 (enExample)
NO (1) NO20082054L (enExample)
SA (1) SA06270365B1 (enExample)
TW (1) TW200800984A (enExample)
UY (1) UY29823A1 (enExample)
WO (1) WO2007040439A1 (enExample)
ZA (1) ZA200802637B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
CA2637392A1 (en) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
WO2008121063A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[ 4,5-b]pyridine-7-carboxamides 704
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
CN103209981B (zh) * 2010-09-10 2016-12-28 盐野义制药株式会社 具有ampk活化作用的杂环稠合咪唑衍生物
JP2017524739A (ja) 2014-07-17 2017-08-31 アンセルムＩｎｓｅｒｍ 神経筋接合部関連疾患の処置方法
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
CN107151235B (zh) * 2016-03-04 2019-12-13 上海市计划生育科学研究所 噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途
MA46888A (fr) * 2016-11-28 2021-06-02 Bristol Myers Squibb Co Inhibiteurs de gsk-3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID24300A (id) * 1997-08-05 2000-07-13 Pfizer Prod Inc 4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
MXPA04007697A (es) * 2002-02-06 2004-11-10 Vertex Pharma Compuestos de heteroarilo utiles como inhibidores de gsk-3.
KR20050002910A (ko) * 2002-03-27 2005-01-10 알타나 파마 아게 신규한 알콕시피리딘-유도체
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
KR100791252B1 (ko) * 2003-01-23 2008-01-03 크리스탈지노믹스(주) 글리코겐 합성효소 키나아제 3β 활성 억제제, 이의제조방법 및 이를 유효성분으로 함유하는 약학 조성물
US7468377B2 (en) * 2003-10-01 2008-12-23 Altana Pharma Ag Imidazopyridine-derivatives as inductible no-synthase inhibitors
BRPI0414933A (pt) * 2003-10-01 2006-11-07 Altana Pharma Ag derivativos de imidazopiridina como inibidores de óxido nìtrico sintase induzìvel
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
CA2637392A1 (en) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same

Also Published As

Publication number Publication date
SA06270365B1 (ar) 2009-12-22
TW200800984A (en) 2008-01-01
ZA200802637B (en) 2008-12-31
NO20082054L (no) 2008-06-02
CN101321754A (zh) 2008-12-10
JP2009510162A (ja) 2009-03-12
UY29823A1 (es) 2007-05-31
AU2006297889A1 (en) 2007-04-12
KR20080057334A (ko) 2008-06-24
CA2624869A1 (en) 2007-04-12
AR057525A1 (es) 2007-12-05
US20080255106A1 (en) 2008-10-16
EP1934217A4 (en) 2010-08-04
EP1934217A1 (en) 2008-06-25
WO2007040439A1 (en) 2007-04-12
BRPI0616663A2 (pt) 2011-06-28

Similar Documents

Publication Publication Date Title
IL189980A0 (en) Novel imidazo [4,5-b]pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
ZA200802637B (en) Novel 2-phenyl-imidazo [4,5-b] pyridine derivatives as inhibitors of glycogen synthase kinase for the treatment of dementia and neurodegenerative disorders
HUS1200009I1 (hu) Pirrolo[2,3-B]piridin származékok, mint protein kináz inhibitorok
IL193740A0 (en) PYRIDO [3, 2 - e] PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM
AP2007003891A0 (en) Quinazolin-4-yl-piperidine and cinnolin-4-yl-pipe ridine derivatives as pde10 inhibitors for the treatment of cns disorders
SG176021A1 (en) 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
EP1984370A4 (en) PROTEIN KINASE ACTIVITY INHIBITING IMIDAZOPYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
IL173139A0 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
ZA201003050B (en) [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or pyridin-2-yle derivatives as protein kinase c-theta
IL196998A0 (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
IL184363A0 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
ZA201106599B (en) Pyrrolo [2,3-b] pyridine derivatives for the inhibition of raf kinases
PL2124944T3 (pl) Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy
IL199378A0 (en) 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors
IL197695A0 (en) 3-amino-pyridine derivatives for the treatment of metabolic disorders
ZA200901015B (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
ZA200809016B (en) 4, 5-Dihydro-[1,2,4] Triazolo [4,3-F] PteridinesS as protein kinase PLK1 inhibitors for the treatment of proliferative disorders
ZA200902730B (en) Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
HK1120263A (en) Novel imidazo [4,5-b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
HK1072253A (en) 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
HK1138515A (en) Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
HK1127045A (en) Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
PL389673A1 (pl) Nowe pochodne 1-(2-pirydylo)-6-podstawione imidazo [1, 2-a][1, 3, 5] triazyny oraz sposób ich wytwarzania
HK1135690A (en) 3-amino-pyridine derivatives for the treatment of metabolic disorders
HU0402163D0 (en) Process for the preparation of risperidone